Blackhawk Growth’s MindBio Therapeutics Looks to Expand Microdosing Clinical Trials
Vancouver, British Columbia – November 01, 2021 – Blackhawk Growth Corp. (CSE:BLR; Frankfurt:0JJ) (the “Corporation” or “Blackhawk”), is pleased to announce that MindBio Therapeutics Pty Ltd (“MindBio”) is working to expand its microdosing clinical trials. MindBio is a multi-disciplinary company pioneering new treatments for mental health conditions using psychedelic medicines, technology assisted mental health interventions and psychedelic assisted psychotherapies.
MindBio is currently undertaking a world’s first clinical trial of its kind. In its phase 1 clinical trial microdosing LSD (Lysergic Acid Diethylamide), MindBio is microdosing LSD to 80 healthy participants who take the drug at home in the same way that they would take any other medication. MindBio will lead phase 2 clinical trials microdosing LSD to patients with major depressive disorder and in patients with late-stage cancer – with those trials set to begin in mid-2022.
Pre-clinical research has demonstrated that psychedelic substances, including LSD, psilocybin, ayahuasca and DMT, affect neuroplasticity after acute and chronic administration. The data generated from in-vitro studies conducted by the Beckley Foundation1 demonstrated neuroplasticity by the presence of Brain Derived Neurotropic Factor (BDNF) in blood plasma. Studies conducted at the University of California, Davis2 have also shown that microdosing psychedelics such as LSD and psilocybin promote increased neurite growth, spine density and synaptogenesis.
MindBio is currently assessing natural psilocybin and potential analogs as a candidate for phase 1 microdosing clinical trials. The company can scale microdosing clinical trials to other substances quickly and cost effectively. MindBio is seeking advice on designing the clinical trial protocols given the potential for psilocybin to treat a number of mental health conditions such as major depressive disorder, PTSD and anxiety.
In addition, Blackhawk’s CEO, Frederick Pels, will be contributing to the psychedelics microdosing discussions at the upcoming Wonderland convention in Miami, where MindBio is a Gold Sponsor. The event is being promoted by conference organiser Microdose as “the biggest psychedelics business event, ever”.
1.https://www.beckleyfoundation.org/2018/06/13/psychedelics-promote-neural-plasticity/
2.https://www.cell.com/cell-reports/fulltext/S2211-1247(18)30755-1
About Blackhawk Growth
Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, and MindBio Therapeutics. Blackhawk continues to bring its investments to cash flow and is growing at an exceeding pace.
The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A
Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.
For further information please contact:
Frederick Pels, Chief Executive Officer
(403)-991-7737
fred@blackhawkgrowth.com
Cautionary Note Regarding Forward-Looking Statement
All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.